Laura Libera, Nora Sahnane, Mario Turri-Zanoni, Fabiana Pettenon, Deborah Marchiori, Paolo Battaglia, Alberto Daniele Arosio, Daniela Furlan, Maurizio Bignami, Paolo Castelnuovo, Fausto Sessa, Carla Facco, Michele Cerati, Stefano La Rosa
{"title":"KRAS/NRAS变异和拷贝数改变对鼻窦黑色素瘤患者的预后分层有影响。","authors":"Laura Libera, Nora Sahnane, Mario Turri-Zanoni, Fabiana Pettenon, Deborah Marchiori, Paolo Battaglia, Alberto Daniele Arosio, Daniela Furlan, Maurizio Bignami, Paolo Castelnuovo, Fausto Sessa, Carla Facco, Michele Cerati, Stefano La Rosa","doi":"10.32074/1591-951X-1088","DOIUrl":null,"url":null,"abstract":"<p><p>Sino-nasal mucosal melanoma (SN-MM) is an aggressive and rare form of melanoma arising from mucosal melanocytes with pathogenesis unrelated to sun exposure. Conversely to cutaneous melanoma (CM), the molecular bases underling SN-MM development and progression are unclear, and no molecular predictive markers have been identified yet. To better define the molecular landscape of SN-MM, a retrospective series of 37 SN-MMs from 31 patients was analysed for both somatic mutations and cytogenetic alterations. The somatic mutation analysis identified the presence of a driver gene pathogenic variant in 54% of cases. In detail, mutually exclusive <i>NRAS</i> mutations were found in 42% of cases, <i>KRAS</i> mutations in 6%, and <i>KIT</i> mutations in 6% of cases. Remarkably, no <i>BRAF</i> mutations were detected. Patients with <i>NRAS</i>-mutated/<i>KRAS</i>-wild type (wt) melanomas showed better outcome than patients with <i>NRAS</i>-wt/<i>KRAS</i>-mutated melanomas, which were associated with multiple recurrences at local or regional sites. On the other hand, focusing on genomic alterations, copy number variants (loss of 1p36, loss of 3p/3q) were identified in 19% of SN-MMs, which showed poor overall survival and short disease-free survival with early metastatic dissemination. This work describes a new integrated characterization of both single nucleotide variants and, for the first time, genomic alteration in SN-MM, providing a new insight into molecular bases of these neoplasms and prompting further efforts for personalized clinical protocols according to tumour aggressiveness.</p>","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"117 2","pages":"121-130"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142291/pdf/","citationCount":"0","resultStr":"{\"title\":\"<i>KRAS/NRAS</i> variants and copy number alterations prognostically stratify patients with sinonasal melanoma.\",\"authors\":\"Laura Libera, Nora Sahnane, Mario Turri-Zanoni, Fabiana Pettenon, Deborah Marchiori, Paolo Battaglia, Alberto Daniele Arosio, Daniela Furlan, Maurizio Bignami, Paolo Castelnuovo, Fausto Sessa, Carla Facco, Michele Cerati, Stefano La Rosa\",\"doi\":\"10.32074/1591-951X-1088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sino-nasal mucosal melanoma (SN-MM) is an aggressive and rare form of melanoma arising from mucosal melanocytes with pathogenesis unrelated to sun exposure. Conversely to cutaneous melanoma (CM), the molecular bases underling SN-MM development and progression are unclear, and no molecular predictive markers have been identified yet. To better define the molecular landscape of SN-MM, a retrospective series of 37 SN-MMs from 31 patients was analysed for both somatic mutations and cytogenetic alterations. The somatic mutation analysis identified the presence of a driver gene pathogenic variant in 54% of cases. In detail, mutually exclusive <i>NRAS</i> mutations were found in 42% of cases, <i>KRAS</i> mutations in 6%, and <i>KIT</i> mutations in 6% of cases. Remarkably, no <i>BRAF</i> mutations were detected. Patients with <i>NRAS</i>-mutated/<i>KRAS</i>-wild type (wt) melanomas showed better outcome than patients with <i>NRAS</i>-wt/<i>KRAS</i>-mutated melanomas, which were associated with multiple recurrences at local or regional sites. On the other hand, focusing on genomic alterations, copy number variants (loss of 1p36, loss of 3p/3q) were identified in 19% of SN-MMs, which showed poor overall survival and short disease-free survival with early metastatic dissemination. This work describes a new integrated characterization of both single nucleotide variants and, for the first time, genomic alteration in SN-MM, providing a new insight into molecular bases of these neoplasms and prompting further efforts for personalized clinical protocols according to tumour aggressiveness.</p>\",\"PeriodicalId\":45893,\"journal\":{\"name\":\"PATHOLOGICA\",\"volume\":\"117 2\",\"pages\":\"121-130\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142291/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PATHOLOGICA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32074/1591-951X-1088\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PATHOLOGICA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32074/1591-951X-1088","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
KRAS/NRAS variants and copy number alterations prognostically stratify patients with sinonasal melanoma.
Sino-nasal mucosal melanoma (SN-MM) is an aggressive and rare form of melanoma arising from mucosal melanocytes with pathogenesis unrelated to sun exposure. Conversely to cutaneous melanoma (CM), the molecular bases underling SN-MM development and progression are unclear, and no molecular predictive markers have been identified yet. To better define the molecular landscape of SN-MM, a retrospective series of 37 SN-MMs from 31 patients was analysed for both somatic mutations and cytogenetic alterations. The somatic mutation analysis identified the presence of a driver gene pathogenic variant in 54% of cases. In detail, mutually exclusive NRAS mutations were found in 42% of cases, KRAS mutations in 6%, and KIT mutations in 6% of cases. Remarkably, no BRAF mutations were detected. Patients with NRAS-mutated/KRAS-wild type (wt) melanomas showed better outcome than patients with NRAS-wt/KRAS-mutated melanomas, which were associated with multiple recurrences at local or regional sites. On the other hand, focusing on genomic alterations, copy number variants (loss of 1p36, loss of 3p/3q) were identified in 19% of SN-MMs, which showed poor overall survival and short disease-free survival with early metastatic dissemination. This work describes a new integrated characterization of both single nucleotide variants and, for the first time, genomic alteration in SN-MM, providing a new insight into molecular bases of these neoplasms and prompting further efforts for personalized clinical protocols according to tumour aggressiveness.